TNSN01076A1 - Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant - Google Patents

Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant

Info

Publication number
TNSN01076A1
TNSN01076A1 TNTNSN01076A TNSN01076A TNSN01076A1 TN SN01076 A1 TNSN01076 A1 TN SN01076A1 TN TNSN01076 A TNTNSN01076 A TN TNSN01076A TN SN01076 A TNSN01076 A TN SN01076A TN SN01076 A1 TNSN01076 A1 TN SN01076A1
Authority
TN
Tunisia
Prior art keywords
growth hormone
antidepressants
associations
compositions containing
hormone secretagogues
Prior art date
Application number
TNTNSN01076A
Other languages
English (en)
Inventor
Robert Busch Frank
Mckowan Welch Willard Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01076A1 publication Critical patent/TNSN01076A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE UNE ASSOCIATION COMPRENANT UN SECRETAGOGUE D'HORMONE DE CROISSANCE ET UN ANTIDEPRESSEUR. ELLE CONCERNE EGALEMENT UNE COMPOSITION COMPRENANT UNE TELLE ASSOCIATION ET UN SUPPORT, VEHICULE OU DILUANT PHARMACEUTIQUEMENT ACCEPTABLE. APPLICATION : UTILISATION DE CETTE ASSOCIATION OU COMPOSITION POUR LE TRAITEMENT DE DIVERSES AFFECTIONS DE PATIENTS SUBISSANT UNE INTERVENTION MEDICALE.
TNTNSN01076A 2000-05-25 2001-05-24 Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant TNSN01076A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20701700P 2000-05-25 2000-05-25

Publications (1)

Publication Number Publication Date
TNSN01076A1 true TNSN01076A1 (fr) 2005-11-10

Family

ID=22768871

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01076A TNSN01076A1 (fr) 2000-05-25 2001-05-24 Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant

Country Status (17)

Country Link
US (1) US20020002137A1 (fr)
EP (1) EP1284753A2 (fr)
JP (1) JP2003534294A (fr)
AR (1) AR028620A1 (fr)
AU (1) AU2001255013A1 (fr)
BR (1) BR0111002A (fr)
CA (1) CA2408036A1 (fr)
DO (1) DOP2001000154A (fr)
EC (1) ECSP014082A (fr)
GT (1) GT200100089A (fr)
MX (1) MXPA02011554A (fr)
PA (1) PA8517701A1 (fr)
PE (1) PE20011262A1 (fr)
SV (1) SV2001000465A (fr)
TN (1) TNSN01076A1 (fr)
UY (1) UY26731A1 (fr)
WO (1) WO2001089570A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
EP1661898A4 (fr) 2003-08-29 2009-04-15 Takeda Pharmaceutical Compose de piperazine bicyclique et utilisation de ce dernier
EP1757290A1 (fr) 2005-08-16 2007-02-28 Zentaris GmbH Derivés de triazole comme ligands du recepteur de l'hormone de croissance
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
WO2009035652A1 (fr) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthèse de benzo[d][1,3]dioxoles et de catéchols deutériés, ainsi que de leurs dérivés
WO2009078999A1 (fr) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1
EP2431035A1 (fr) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Nouveaux dérivés de triazole avec activité de récepteur améliorée et propriétés de biodisponibilité en tant qu'antagonistes de ghréline de récepteurs de secrétagogue d'hormone de croissance
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
EP4232450A1 (fr) 2020-10-21 2023-08-30 Aligos Therapeutics, Inc. Composés bicycliques
WO2022266193A1 (fr) 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Composés bicycliques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Also Published As

Publication number Publication date
WO2001089570A3 (fr) 2002-06-20
SV2001000465A (es) 2001-07-03
US20020002137A1 (en) 2002-01-03
JP2003534294A (ja) 2003-11-18
GT200100089A (es) 2002-01-11
AR028620A1 (es) 2003-05-14
CA2408036A1 (fr) 2001-11-29
WO2001089570A2 (fr) 2001-11-29
PA8517701A1 (es) 2002-12-30
BR0111002A (pt) 2003-04-15
ECSP014082A (es) 2002-04-23
MXPA02011554A (es) 2003-04-25
UY26731A1 (es) 2001-12-28
DOP2001000154A (es) 2002-05-15
EP1284753A2 (fr) 2003-02-26
PE20011262A1 (es) 2001-12-11
AU2001255013A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
MA28072A1 (fr) Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
ATE165093T1 (de) Aminoketonderivate
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
HUP0004339A2 (hu) Nõk kezelési eljárása menopauzát követõen ultra-alacsony dózisú ösztrogénnel
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
BG105302A (en) Means for improving cognition
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
TNSN98113A1 (fr) Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline.
ATE426402T1 (de) Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l
SE9801495D0 (sv) Protein formulationa
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
MA27474A1 (fr) Vaccin